Volume 24, Number 7—July 2018
Perspective
Progress in Vaccine-Preventable and Respiratory Infectious Diseases—First 10 Years of the CDC National Center for Immunization and Respiratory Diseases, 2006–2015
Table 1
Strategic priorities | Implementation examples |
---|---|
Improve immunization programs |
Implemented central vaccine distribution and Vaccine Tracking System (VtrkS); supported development of adolescent platform for vaccination |
Strengthen systems to evaluate policy effectiveness |
Initiated annual estimation of influenza vaccine impact based on influenza surveillance, vaccine effectiveness studies, and immunization coverage surveys; introduced National Immunization Survey-Teen and quality standards for systems monitoring school-based immunization coverage |
Accelerate vaccine-preventable disease reduction worldwide |
Implementing partner for the Hib Initiative (2005–2009), which facilitated decisions to introduce Haemophilus influenzae b (Hib)–containing vaccine in all Global Alliance for Vaccines and Immunization–eligible countries and provided model framework for subsequent new vaccine introduction efforts |
Reduce complications of pneumonia and influenza |
Issued evidence-based guidance for influenza antiviral use to reduce severity of influenza illness |
Improve pandemic preparedness |
Enhanced laboratory detection of novel influenza viruses and led response to first influenza pandemic of the 21st century |
Strengthen response to respiratory outbreaks |
Developed Unexplained Respiratory Disease Outbreak tool kit for state, local, and international partners (https://www.cdc.gov/urdo/index.html) |
Develop and promote strategies to reduce respiratory infections, vaccine-preventable diseases, and control antimicrobial resistance |
Expanded the Advisory Committee on Immunization Practices recommendations for annual influenza vaccination and age groups recommended for pneumococcal conjugate vaccination; incorporated Get Smart: “know when antibiotics work” activities into national strategy to reduce antimicrobial resistance |
Improve identification of causes of respiratory infections | Validated TaqMan technology for multiple pathogen diagnosis of respiratory syndromes; completed multicenter studies of etiology of pneumonia in the community in adults and children |
1Current affiliation: Emory University, Atlanta, Georgia, USA.
2Current affiliation: World Health Organization, Cairo, Egypt.
Page created: June 18, 2018
Page updated: June 18, 2018
Page reviewed: June 18, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.